Arena Pharmaceuticals has turned its bad luck around, and could be on the path to something huge.
Break out the hand sanitizer -- with these tips, you'll be shaking hand after hand at your next industry conference.
We hear from executives from Alnylam, Arena Pharmaceuticals, and Spark Therapeutics at the biggest healthcare conference of the year.
All your Motley Fool coverage of the J.P. Morgan Healthcare Conference in one place.
These articles caught our readers' attention in droves over the past year.
Bruce Linton talks with us about running the biggest pure-play marijuana company, and the future of the marijuana industry.
The biotech sector is full of millionaire-maker stocks. But how do you separate the gems from the junk?
Find out why our energy experts think General Motors, NV5, and Transocean have the potential to see huge wins in the long run.
Looking for value stocks to add to your portfolio this quarter? We have some great suggestions.
Does it seem like growth investors have all the fun? Fear not -- there are also plenty of value stocks out there that require a little bravery.
Feeling brave? These value stocks could provide incredible returns to investors willing to take on the risk.
A trio of our Foolish contributors think these stocks could be incredible bargains -- but they are not investments for the faint of heart.
Investors looking for reliable returns should consider CVS Health, Dick's Sporting Goods, and Berkshire Hathaway.
Will you be prepared when opportunity strikes? Learn how to craft the perfect compelling elevator pitch.
Veeva's president discusses the cloud solution company he co-founded, from its small beginnings in healthcare CRM to its latest Vault products and expansion outside life sciences.
New year, same Industry Focus crew -- but with new resolutions for 2017! Find out how we're resolving to improve our financial lives this year.
Creating a watchlist is a must for any serious investor.
All your Motley Fool coverage of the JP Morgan Healthcare Conference in one place.
It is crossover week on Industry Focus as the team looks at popular consumer-retail trends and their counterparts in healthcare.
Did the FDA do the right thing approving eteplirsen?